Enzalutamide
- Generic Name
- Enzalutamide
- Brand Names
- Xtandi, Enzalutamide Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16F4N4O2S
- CAS Number
- 915087-33-1
- Unique Ingredient Identifier
- 93T0T9GKNU
- Background
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieve...
- Indication
Enzalutamide is indicated for the treatment of castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (mCRPC). It is also used in combination with talazoparib for the treatment of adult patients with HRR gene-mutated mCRPC.
- Associated Conditions
- Castration Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 12
- Registration Number
- NCT02225093
- Locations
- 🇲🇩
Arensia, Chisinau, Moldova, Republic of
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 37
- Registration Number
- NCT02215096
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT02207504
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2023-05-31
- Target Recruit Count
- 96
- Registration Number
- NCT02203695
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Suburban Hospital, Bethesda, Maryland, United States
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
- Conditions
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 120
- Registration Number
- NCT02204072
- Locations
- 🇪🇸
Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain
🇪🇸Hospital Ramón y Cajal, Madrid, Spain
🇬🇧The Clatterbridge Cancer Centre, Bebington, Wirral, United Kingdom
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 49
- Registration Number
- NCT02199197
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Phase III Radium 223 mCRPC-PEACE III
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2024-04-05
- Target Recruit Count
- 446
- Registration Number
- NCT02194842
- Locations
- 🇮🇹
Ospedale B.Ramazzini, Carpi, Italy
🇨🇦Hamilton And District Urology Association, Hamilton, Ontario, Canada
🇨🇦London Regional Cancer Center, London, Ontario, Canada
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
- Conditions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Kenneth Pienta, MD
- Registration Number
- NCT02159690
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men
- Conditions
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 28
- Registration Number
- NCT02138799
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men
- Conditions
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 16
- Registration Number
- NCT02138162
- Locations
- 🇧🇬
Comac Medical Ltd., Sofia, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.